• In the first quarter ended March 31, 2026, agilon health reported revenue of US$1.42 billion, net income of US$48.92 million, and basic earnings per share from continuing operations of US$1.80, all compared with the same period a year earlier.
• Despite lower revenue year-on-year, agilon health’s sharp improvement in profitability and higher earnings per share coincided with raised 2026 sales guidance driven by better medical margins.
• With agilon health posting stronger profitability despite softer revenue, we’ll now examine how this improved medical margin profile affects its investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

agilon health Investment Narrative Recap

To own agilon health, you need to believe its value based care model can translate into durable, improving medical margins, even with choppy membership and revenue. The latest quarter supports that focus, with higher profitability and raised 2026 sales guidance tied to better medical margins. In the near term, the key catalyst is whether this margin improvement can persist, while the biggest risk remains execution missteps in managing medical costs and contracts; this news does not remove that concern.

Among recent developments, the investigation into potential breaches of fiduciary duty following earlier securities lawsuits is especially relevant. Those cases center on past disclosures about medical margins and cost control, the same areas now driving improved results and higher guidance. For investors, the legal overhang sits alongside the margin story, reminding you that even as the operating profile improves, governance and disclosure risks can still influence how the market treats agilon health’s progress.

Yet behind the better margins and upbeat guidance, there is still the unresolved legal overhang that investors should be aware of as it could...

agilon health’s narrative projects $6.3 billion revenue and $320.9 million earnings by 2029.

Uncover how agilon health's forecasts yield a $19.67 fair value, a 72% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were once projecting revenue of about US$8.7 billion and a return to roughly breakeven earnings, which is far more upbeat than consensus and could look very different now that Q1 2026 highlighted both stronger margins and ongoing legal and operational risks.

Explore 4 other fair value estimates on agilon health - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your agilon health research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free agilon health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate agilon health's overall financial health at a glance.

No Opportunity In agilon health?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.